BridgeBio Pharma (BBIO) Amortization of Deferred Charges (2024 - 2026)

BridgeBio Pharma has disclosed Amortization of Deferred Charges across 3 years of filings, most recently posting $1.8 million for Q1 2026.

• Amortization of Deferred Charges for Q1 2026 came in at $1.8 million, up 12.21% year-over-year; the trailing twelve-month figure through Mar 2026 was -$585000.0 (changed N/A YoY), and the FY2023 annual result was $8.9 million, changed N/A from the prior year.
• Amortization of Deferred Charges came in at $1.8 million for Q1 2026 at BridgeBio Pharma, up from -$4.5 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $1.8 million in Q1 2026 to a low of -$5.4 million in Q4 2024.
• The 3-year median for Amortization of Deferred Charges is $492000.0 (2024), against an average of -$915000.0.
• Peak annual rise in Amortization of Deferred Charges reached 16.37% in 2025, while the deepest fall reached 0.81% in 2025.
• BridgeBio Pharma's Amortization of Deferred Charges stood at -$5.4 million in 2024, then rose by 16.37% to -$4.5 million in 2025, then jumped by 140.29% to $1.8 million in 2026.
• The last three Amortization of Deferred Charges figures came in at $1.8 million (Q1 2026), -$4.5 million (Q4 2025), and $490000.0 (Q3 2025), per Business Quant data.